x

Posted 19 April, 2023

Disc Medicine, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:IRON in a 8-K filed on 19 April, 2023.


  On April 18, 2023, Jay T. Backstrom, M.D., M.P.H., a member of the Board of Directors (the "Board) of Disc Medicine, Inc. (the "Company"), notified the Company of his resignation from the Board effective as of the close of business on June 9, 2023. Dr. Backstrom resigned in part to focus on his role as the Chief Executive Officer of Scholar Rock Holdings Corporation.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Disc Medicine, Inc.
Health Care/Life Sciences • Biotechnology
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel treatments for hematologic disorders. Its programs include Bitopertin, DISC-0974, and DISC-3405. The company was founded in October 2017 and is headquartered in Watertown, MA.
Market Cap
$1.78B
View Company Details
Disc Medicine, Inc. by TradingView
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On April 18, 2023, Jay T. Backstrom, M.D., M.P.H., a member of the Board of Directors (the "Board) of Disc Medicine, Inc. (the "Company"), notified the Company of his resignation from the Board effective as of the close of business on June 9, 2023. Dr. Backstrom resigned in part to focus on his role as the Chief Executive Officer of Scholar Rock Holdings Corporation. Dr. Backstrom's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.